Bruker Corp BRKR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BRKR is a good fit for your portfolio.
News
-
Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference
-
Bruker Announces Date and Time of First Quarter 2024 Earnings Release and Webcast
-
Bruker to Acquire the NanoString Business in an Asset Deal
-
Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies
-
Bruker Introduces Novel NMR Scientific Capabilities for Structural Biology Discoveries in Membrane Proteins and Protein Aggregates
-
Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research
-
Bruker Selected as ‘Company of the Year’ by Instrument Business Outlook
-
Bruker Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO
Trading Information
- Previous Close Price
- $78.01
- Day Range
- $78.02–80.02
- 52-Week Range
- $53.79–94.86
- Bid/Ask
- $78.93 / $78.97
- Market Cap
- $11.47 Bil
- Volume/Avg
- 1.3 Mil / 861,418
Key Statistics
- Price/Earnings (Normalized)
- 30.24
- Price/Sales
- 3.87
- Dividend Yield (Trailing)
- 0.26%
- Dividend Yield (Forward)
- 0.26%
- Total Yield
- 1.52%
Company Profile
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 9,707
- Website
- https://www.bruker.com
Comparables
Valuation
|
Metric
|
BRKR
|
MASS
|
AZTA
|
|---|---|---|---|
Price/Earnings (Normalized) | 30.24 | — | 194.30 |
Price/Book Value | 8.22 | 1.12 | 1.20 |
Price/Sales | 3.87 | 3.66 | 5.10 |
Price/Cash Flow | 26.22 | — | 100.81 |
Price/Earnings
BRKR
MASS
AZTA
Financial Strength
|
Metric
|
BRKR
|
MASS
|
AZTA
|
|---|---|---|---|
Quick Ratio | 0.92 | 6.86 | 4.84 |
Current Ratio | 1.80 | 7.71 | 5.87 |
Interest Coverage | 33.50 | −213.38 | — |
Quick Ratio
BRKR
MASS
AZTA
Profitability
|
Metric
|
BRKR
|
MASS
|
AZTA
|
|---|---|---|---|
Return on Assets (Normalized) | 9.84% | −12.31% | −0.66% |
Return on Equity (Normalized) | 31.07% | −15.14% | −0.75% |
Return on Invested Capital (Normalized) | 15.25% | −17.75% | −1.97% |
Return on Assets
BRKR
MASS
AZTA
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Sjtdmnmz | Ncnzl | $183.9 Bil | |
SYK
| Stryker Corp | Jglksmsgt | Hppbw | $128.0 Bil | |
MDT
| Medtronic PLC | Wfwllvh | Cwxtt | $106.5 Bil | |
BSX
| Boston Scientific Corp | Yzbmpfwc | Mqnxkd | $105.6 Bil | |
EW
| Edwards Lifesciences Corp | Xxnwglnk | Fzzpwh | $51.0 Bil | |
DXCM
| DexCom Inc | Yhxftymvnh | Cggp | $50.4 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Wzkpqbbbk | Xjmvs | $24.7 Bil | |
PHG
| Koninklijke Philips NV ADR | Flpbslqmj | Skbxxyg | $24.5 Bil | |
ALGN
| Align Technology Inc | Gcqktfc | Pkhkhsv | $21.3 Bil | |
PODD
| Insulet Corp | Cgctsztm | Fmxkp | $12.0 Bil |